review quotes glp-1 glp 1 The promise and peril of agonists: What we do (and don't) know as of August 2024 In the gray world of

GLP-1s 101 GLP-1s are a class of drugs first approved by the Food and Drug Administration in 2005 to manage blood sugar in people with type 2 diabetes

Whether you are currently on a GLP-1 medication considering keto, already following a ketogenic diet exploring peptide therapy, or planning an exit strategy from GLP-1 that actually preserves your results, this is the reference you will come back to

Truveta Research study : At 52 weeks, weight loss was 18.2% for Mounjaro (tirzepatide ADM) compared to 10.6% for Ozempic (semaglutide ADM) for patients without type 2 diabetes (T2D) The lower percentages in the Truveta Research study likely reflect a shorter timeframe (52 weeks instead of 72) and the use of ADM versions, which can have lower doses

(66), the mechanism of sinomenine inhibiting arthritis in CIA rats may be related to regulating the frequency of Treg and Th17 cells in intestinal lymph nodes and transporting lymphocytes (especially Treg cells) from the intestine to the joints